The American Cancer Society (ACS) has introduced updated guidelines aimed at enhancing colorectal cancer screening methods, particularly in response to rising incidence rates among younger individuals. This revised approach now incorporates a blood testing option alongside traditional screening methods, signifying a shift in the strategies employed to identify cancer at treatable stages.
:max_bytes(150000):strip_icc():format(jpeg)/colon-cancer-screening-tout-031424-20def394ad31433e9c01310eddd1f418.jpg)
On 27th May, the ACS announced these new recommendations, which advocate for the inclusion of a blood test, specifically the Shield test from Guardant Health, as a viable screening alternative. This test, which received FDA approval in 2024, analyses fragments of tumour DNA in the bloodstream. Although the blood test has demonstrated an 83% accuracy in detecting cancer cases identified through colonoscopies, it appears less effective in spotting advanced precancerous lesions, achieving only a 13% detection rate.
While the new guidelines broaden the range of screening tools available, the ACS maintains that colonoscopy remains the preferred standard for colorectal cancer detection. As stated in the announcement, blood tests are recommended primarily for individuals who are reluctant to undergo either a colonoscopy or a stool-based test. The ACS insists that in cases where the blood test returns abnormal results, a follow-up colonoscopy is essential for accurate diagnosis and further examination.
Dr. Robert Smith, senior vice president of early cancer detection science at the ACS, highlighted the necessity of re-evaluating colorectal cancer as not only a treatable but also a largely preventable disease. He expressed optimism that by providing more screening options, a greater number of eligible adults will engage in essential testing, thereby bridging the screening gap and facilitating early cancer detection.
The introduction of these blood tests coincides with the alarming trend of increasing colorectal cancer rates among the young. Statistics indicate that approximately one in five colorectal cancer diagnoses now occurs in individuals under the age of 55. This demographic shift is troubling, as it marks a reversal of the trend seen in older age groups where overall colorectal cancer rates have decreased over the past decade.
The ACS advocates that adults aged 45 and above should routinely engage in colorectal cancer screenings. Additionally, individuals exhibiting symptoms associated with the disease—including changes in bowel habits, rectal bleeding, and unexplained weight loss—are urged to seek medical evaluation. Early detection is crucial; symptoms often manifest only once the cancer has progressed, making proactive screening vital for successful treatment outcomes.
Dr. William Dahut, chief scientific officer at the ACS, reiterated the necessity for these updated guidelines. He emphasized the importance of ensuring that cancer screening accessibility extends to underserved, rural, and minority populations. The goal is clear: by diversifying the screening toolkit, the ACS hopes to make preventive cancer care available for everyone, thereby improving health outcomes across various demographics.
The Shield test, as well as other modern screening alternatives, forms part of a broader strategy to tackle the increasing rates of colorectal cancer. The ACS’s commitment to revising its guidelines reflects a recognition of the changing patterns in cancer prevalence and the urgent need for adaptive healthcare responses to ensure no one is left behind.
In summary, the ACS’s new guidelines represent a proactive and inclusive approach to colorectal cancer screening, aiming to catch more cases at earlier, more treatable stages. By promoting awareness and facilitating access to varied screening options, the organisation hopes to significantly reduce the incidence and impact of this potentially preventable disease.